Companies /Healthcare

VBI Vaccines Inc

NASDAQ: VBIV Biotechnology

$0.07

▲ $0.00 (+0.00%) today

Markets closed · 7:54am ET

VBIV at a Glance

Valuation

Market cap: $1.9M

Profitability

Revenue (TTM): $9.4M
EPS (TTM): $-3.54

Price

Street target: $5.00

Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: VBIV vbivaccines.com

About VBIV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company is headquartered in Cambridge, Massachusetts.

VBIV Coverage

11:55am ET

Investing

Markets Pump the Brakes After Thursday Rally: Analysts Upgrade or Downgrade Intel, Occidental, Roku and More

Friday’s additional top analyst upgrades and downgrades were on Freeport-McMoRan, GSK, Intel, L3Harris Technologies, Occidental Petroleum, Roku, Six Flags Entertainment, Spirit AeroSystems, Sprouts Farmers Market, TuSimple and more.

FCX GDDY GSK

Chris Lange

11:45am ET

Investing

Wednesday Afternoon’s Analyst Upgrades and Downgrades: Inovio Pharmaceuticals, McDonald’s, VBI Vaccines, Wingstop and More

Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.

ALT CODX CTAS

Chris Lange

Frequently Asked Questions

What does VBIV do?

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company is headquartered in Cambridge, Massachusetts.

What is the VBIV stock price target?

The Wall Street consensus 12-month price target for VBIV is $5.00.